ClinicalTrials.gg
Status unknownNCT05576285RISCUpdated Feb 9, 2023

Retinal Imaging Study of Children That Might be at Risk of Having Retinal Hemorrhages

An observational study in Retinal Hemorrhage, Bilateral, Retinal Hemorrhage, Left Eye and Retinal Hemorrhage, Right Eye, sponsored by Region Stockholm. Status unknown at 1 site in Sweden. Open to participants aged 4 Weeks to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-09.

Sponsored by Region Stockholm · Observational

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
4 Weeks to 14 Years
Sex
All
01

Study summary

This is a clinical trial in which we will learn about the retinal findings in three clinical groups of children, who might be at risk of having retinal hemorrhages (RH). The aim of the study is to explore the occurrence of moderate to severe retinal hemorrhages in critically ill children, children with intracranial hemorrhages, hydrocephalus or signs of elevated intracranial pressure and in children with benign enlargement of subarachnoid spaces (BESS).

  1. Are RHs associated with BESS?
  2. What is the prevalence, distribution and extent of RHs in critically ill children?
  3. What is the prevalence, distribution and extent of RHs in children with traumatic brain injury?
  4. Does the prevalence, distribution and extent of RHs differ in children with witnessed traumatic brain injury from children with traumatic brain injury of unknown origin?
  5. To what extent do the causes of RHs affect visual acuity, initially and during recovery? A retinal ophthalmoscopy through dilated pupils will be conducted and a fundus photograph will be taken by a handheld, non-touch camera.
Read the detailed description

The prospective study will take place at university hospitals in three Swedish regions, Stockholm, Skåne and Västra Götaland. The data collection from the three regions will proceed in parallel over a three-year period. An estimated number of children will be 400-500 per year. The study children will be consecutively referred to the pediatric ophthalmology units, where the ophthalmological examinations will take place. Bedside examinations will be performed when indicated at the pediatric intensive care units. Retinal fundus examination will be performed according to clinical standards following administration of pupil dilating eye drops in each eye. Visual function will be evaluated if ophthalmic abnormalities are detected.

Prospective observational study Group 1: All infants ≤ 18 months of age, who undergo neuroradiological examinations of the brain on the indication increased head circumference.

Group 2: All critically ill children \< 15 years of age, cared for at the hospitals, with neurological symptoms, that require neuroradiological examination of the brain.

Group 3: All children ≤ 2 years of age, who undergo emergency neuroradiological examinations of the head at the hospitals.

02

Conditions studied

  • Retinal Hemorrhage, Bilateral
  • Retinal Hemorrhage, Left Eye
  • Retinal Hemorrhage, Right Eye

Keywords

  • retinal hemorrhage
03

In context

Lead sponsor

Region Stockholm is the lead sponsor of 120 studies on the registry; 69 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Weeks to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Residents in the Stockholm region, the Skåne region and the Västra Götaland region

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants ≤ 18 months of age, who undergo neuroradiological examinations of the brain on the indication increased head circumference
  • Children \< 15 years of age, cared for at the ICU, with neurological symptoms, that require neuroradiological examination of the brain
  • Children \< 5 years of age, who undergo emergency neuroradiological examinations of the head at the hospitals

Exclusion criteria

Exclusion Criteria

- Infants with intraventricular hemorrhages due to prematurity, in the absence of increased head circumference

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Accelerating head growth in infancy

    Infants \<=18 months of age referred to head ultrasound because of accelerating head growth

    Diagnostic Test: ophthalmoscopy and fundus photography through dilated pupills

  • Children at ICU with neurological symptoms that require brain MRI or CT

    Children \< 15 years of age who are cared for at ICU becaus of neurological symptoms that require brain MRI or CT scans

    Diagnostic Test: ophthalmoscopy and fundus photography through dilated pupills

  • Children entering the emergency department with the need of acute brain CT

    Children \< 2 years of age that enter the emergency department because of brainthreatening conditions that require acute brain CT scans

    Diagnostic Test: ophthalmoscopy and fundus photography through dilated pupills

Interventions

  • Diagnostic testophthalmoscopy and fundus photography through dilated pupills

    ophthalmoscopy and fundus photography through dilated pupills

06

What researchers measure

Primary outcomes

  1. Number of patients with retinal hemorrhages

    Ophthalmoloscopy findings registered in protocol and fundus photographs

    Time frame: 20 minutes

  2. Number and distribution of retinal hemorrhages in eyes

    Ophthalmoloscopy findings registered in protocol and fundus photographs

    Time frame: 20 minutes

Secondary outcomes

  1. Visual function

    Following and fixating LH face

    Time frame: 10 minutes

  2. Eye movements

    Following and fixating LH face

    Time frame: 10 minutes

07

Study locations

1 of 1 sites recruiting
  • Kerstin Margareta Hellgren
    Stockholm, 17164, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2022
First posted
Oct 12, 2022
StartActual
Feb 8, 2023
Primary completionEst.
Feb 8, 2026
CompletionEst.
Feb 8, 2026
Last update
Feb 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05576285
Lead sponsor
Region Stockholm
Responsible party
Kerstin Hellgren (Associate professor, Region Stockholm) — Principal investigator
First posted
Oct 12, 2022
Start date
Feb 8, 2023
Primary completion
Feb 8, 2026 (estimated)
Completion
Feb 8, 2026 (estimated)
Last update
Feb 9, 2023

Study contacts

Hannamaria Öhnell, MD, PhD
Contact
hanna_maria.ohnell@med.lu.se
+4640-332781
Gunilla Magnusson, MD, PhD
Contact
gunilla.magnusson@vgregion.se
+4631- 343 32 56
Kerstin M Hellgren, MD, PhD
principal investigator · Region Stockholm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion